Pancreatic Beta Cell Proliferation via DYRK1A and TGFβ Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing human beta cell proliferation are insufficient for therapeutic applications in treating type 1 and type 2 diabetes, as they result in rates lower than 5% per day, which is not practically effective for restoring beta cell mass within a therapeutically reasonable time period.
Innovation Solution
A method involving the combined use of a dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and a transforming growth factor beta (TGFβ) superfamily signaling pathway inhibitor to increase pancreatic beta cell proliferation, achieving rates of up to 15-20% per day.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If small molecule inhibitors of DYRK1A are used to induce human beta cell proliferation, then beta cell proliferation rate increases to 1.5-3% per day, but this rate is insufficient for practical therapy to treat T1D and T2D patients within a therapeutically reasonable time period
Solution Approach 1:
The patent combines two different inhibition approaches: DYRK1A inhibition (using small molecules like harmine, INDY, GNF4877, or 5-IT) and TGFβ superfamily signaling pathway inhibition (using inhibitors like SB431542, A-83-01, or LDN193189). This combination therapy achieves synergistic effects, pushing beta cell proliferation rates from 1.5-3% per day to at least 5% per day, thereby resolving the contradiction between achieving sufficient proliferation rate and doing so within a therapeutically reasonable time frame.
2Productivity
If higher beta cell proliferation rates are achieved through combination therapy, then beta cell mass increases rapidly at 5% or more per day, but the complexity of the treatment protocol increases due to use of multiple inhibitors
Solution Approach 1:
The patent merges two pharmacological interventions into a single combination therapy protocol. Rather than using complex multi-component therapies or genetic modifications, the invention combines two well-defined small molecule inhibitor classes (DYRK1A inhibitors and TGFβ pathway inhibitors) that can be administered together, achieving high proliferation rates while maintaining relative treatment simplicity.
Solution Approach 2:
The patent changes the pharmacological parameters by introducing specific inhibitor concentration ranges and treatment durations that optimize the synergistic effect. By carefully controlling the dosing parameters of both DYRK1A inhibitors and TGFβ pathway inhibitors, the therapy achieves high proliferation rates without requiring overly complex administration protocols.
3Loss of time
If rapid beta cell proliferation is induced to restore beta cell mass quickly, then treatment time is reduced, but the risk of losing beta cell differentiation or function may increase
Solution Approach 1:
The patent optimizes treatment parameters including inhibitor concentrations, treatment duration, and timing to achieve rapid proliferation while preserving beta cell quality. The synergistic combination allows for controlled proliferation at 5% or more per day without the need for extended treatment periods that might compromise cell differentiation, thereby maintaining both speed and reliability.
Solution Approach 2:
The patent incorporates monitoring of beta cell proliferation markers and functional markers to ensure that rapid proliferation does not compromise differentiation. By using proliferation markers (such as Ki-67 or BrdU incorporation) and functional markers (such as insulin secretion capacity), the therapy can be adjusted to maintain the balance between rapid mass restoration and preservation of cell quality.
Data Source
AI summary
The present invention relates to a method of increasing cell proliferation in a population of pancreatic beta cells and a method of treating a subject for a condition associated with an insufficient level of insulin secretion. Also disclosed is a composition. The composition includes a dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1 A) inhibitor and a transforming growth factor beta (TGFP) superfamily signaling pathway inhibitor.